Company Overview and News
One of the most trusted brands of Stanley Black & Decker, Inc. (SWK - Free Report) , CRAFTSMAN, yesterday announced the adoption of a brand identity and launch of an array of products, tools and accessories. It’s worth noting here that CRAFTSMAN became part of Stanley Black in March 2017, when the Stanley Black acquired it from Sears Holdings Corporation . CRAFTSMAN strongly complements the company’s existing tools and storage brands.
SHLD SWK CFX SHLDW GTLS
The Craftsman brand has relaunched under new ownership, with Stanley Black & Decker Inc. SWK, +0.71% adding new tools to the lineup and introducing a new logo. Stanley Black & Decker bought the Craftsman brand from Sears Holdings Corp. SHLD, +0.00% in 2017 for about $900 million in cash. The new tool lineup includes a VersaStack portable storage system and a new range of tape measures, including pro-quality tape measures with up to 13 feet of standout.
2018-09-14 investorplace - 1
A new round of tariffs sucked the wind out of the markets on Friday, but not enough to snowball any sort of large declines into the weekend. U.S. equities traded around flat on Friday, surprising given the decent rally we’ve had this week. Let’s look at our top stock trades.
SHLD GE GEC KR AAPL GNE SHLDW ETSY
(Sept 14): Investors shrugged off another quarterly loss by Sears Holdings Corp, sending the shares jumping as much as 20% in early trade, after the retailer said its performance stabilized this summer.
SHLD TGT SHLDW
Sears Holdings Corp. (NASDAQ: SHLD) reported its fiscal second-quarter financial results after the markets closed on Thursday. In a surprising reaction to these results, investors sent shares higher even though this retail chain is on its last legs.
Elon Musk’s SpaceX, demonstrating its founder and chief executive’s penchant for showmanship, announced that it had signed up the first private passenger seeking to fly around the moon. But the company provided no timetable or other details about the plan.
SHLD VLKAF FB SHLDW
2018-09-14 wolfstreet - 1
The headline said that shares of Sears Holding jumped “more than 7%” in late trading after it reported more losses and store closures and plunging revenues in its second quarter earnings report. By the time I checked it out, the stuff was up 22%, to a whopping $1.48, after having been down 9% during the day.
Sears Holdings Corp reported a smaller decline in quarterly same-store sales on Thursday, but warned again that there is doubt about the company's continued operation as it awaits approval to sell some of its businesses to its chief executive's hedge fund.
(Reuters) - Sears Holdings Corp (SHLD.O) reported a smaller decline in quarterly same-store sales on Thursday, but warned again that there is doubt about the company’s continued operation as it awaits approval to sell some of its businesses to its chief executive’s hedge fund.
One of my best short ideas this year so far has been struggling retailer Sears Holdings (SHLD). As the company continues to close stores and try to get its perilous financial situation in check, shares have plunged to new lows. Unfortunately while shares have surged thanks to the latest quarterly report, it didn't do too much to ease fears that the worst may be yet to come.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET